Back to Clinical Trials

Brief Title: Disitamab Vedotin in Subjects With HER2 Expressing Urothelial Carcinoma

A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination With Pembrolizumab in Subjects With Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2

INTRODUCTION

  • Org Study ID: RC48G001
  • Secondary ID: N/A
  • NCT ID: NCT04879329
  • Sponsor: Seagen, a wholly owned subsidiary of Pfizer

DESCRIPTION

To read more about what this clinical trial is about please click this link:

RC48G001_PFM_PatientTrialCard_US_ENG_V1.0_30Aug2022_USM_DV_2022_0018

 

BRIEF SUMMARY

This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants.

Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic).

It will also study what side effects happen when participants get the drug. A side effect is anything a drug does to your body besides treating the disease.

  • Overall Status
    Recruiting
  • Start Date
    May 3, 2022
  • Phase
    Phase 2
  • Study Type
    Interventional

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Confirmed Objective Response Rate (cORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1) by blinded independent central review (BICR) (Cohorts A

Primary Outcome 1 - Timeframe: Duration of treatment; approximately 2 years

Primary Outcome 2 - Measure: B

Primary Outcome 2 - Timeframe: Approximately 2 years

Primary Outcome 3 - Measure: C

Primary Outcome 3 - Timeframe: Approximately 2 years

Primary Outcome 4 - Measure: and G)

Primary Outcome 4 - Timeframe: Approximately 2 years

Primary Outcome 5 - Measure: Incidence of adverse events (AEs) (Cohorts D and E)

Primary Outcome 5 - Timeframe: Approximately 2 years

Primary Outcome 6 - Measure: Incidence of dose alterations (Cohorts D and E)

Primary Outcome 6 - Timeframe: Approximately 2 years

Primary Outcome 7 - Measure: Incidence of laboratory abnormalities (Cohorts D and E)

Primary Outcome 7 - Timeframe: Through 30-37 days following the last dose of DV; up to approximately 2 years

Primary Outcome 8 - Measure: Incidence of electrocardiogram (ECG) abnormalities (Cohorts D and E)

Primary Outcome 8 - Timeframe: Through 30-37 days following the last dose of DV; up to approximately 2 years

Primary Outcome 9 - Measure: Change from baseline of left ventricular ejection fraction (LVEF) (Cohorts D and E)

Primary Outcome 9 - Timeframe: Through 30-37 days following the last dose of DV; up to approximately 2 years

Primary Outcome 10 - Measure: Pharmacokinetic (PK) parameter - Area under the curve (AUC) (Cohorts D and E)

Primary Outcome 10 - Timeframe: Through 30-37 days following the last dose of DV; up to approximately 2 years

Primary Outcome 11 - Measure: PK parameter - Maximum concentration (Cmax) (Cohorts D and E)

Primary Outcome 11 - Timeframe: N/A

Primary Outcome 12 - Measure: PK parameter - Time to maximum concentration (Tmax) (Cohorts D and E)

Primary Outcome 12 - Timeframe: N/A

Primary Outcome 13 - Measure: PK parameter - Trough concentration (Ctrough) (Cohorts D and E)

Primary Outcome 13 - Timeframe: N/A

CONDITION

  • Urothelial Carcinoma

ELIGIBILITY

Inclusion Criteria:
Cohorts A and B
* Histopathologically-confirmed, locally-advanced, unresectable or metastatic urothelial cancer (LA/mUC), including UC originating from the renal pelvis, ureters, bladder, or urethra

- * Participants must have received only 1 or 2 lines of prior systemic treatment for LA/mUC, including 1 line of platinum-containing chemotherapy

- * At least one measurable lesion by investigator assessment based on RECIST version 1.1.

- * HER2-expression status determined by the central laboratory to be IHC 1+, 2+ or 3+, in the provided tumor sample

- * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
Cohort C
* Histopathologically-confirmed LA/mUC, including UC originating from the renal pelvis, ureters, bladder, or urethra

- * No prior systemic therapy for LA/mUC
* Neoadjuvant or adjuvant therapy, including PD-(L)1 inhibitors, is acceptable, if disease recurrence/progression occurred more than 12 months after the last dose of systemic therapy

- * At least one measurable lesion by investigator assessment based on RECIST v1.1.

- * Participant is eligible to receive cisplatin- or carboplatin- containing chemotherapy per investigator evaluation

- * HER2-expression status determined by the central laboratory to be IHC 1+, 2+ or 3+, on the provided tumor tissue sample

- * ECOG performance status of 0, 1, or 2
Cohort D
* Histopathologically-confirmed LA/mUC, including UC originating from the renal pelvis, ureters, bladder, or urethra

- * Based on a participant's eligibility to receive treatment with standard of care therapies in Japan, participants must have received all of the following lines of therapy for LA/mUC:
* a. One prior line of platinum-containing chemotherapy.

- * b. Prior therapy with PD-(L)1 inhibitors as (neo)adjuvant therapy, first-line maintenance therapy or as second line treatment.

- * c. Prior enfortumab vedotin therapy.

- * At least one measurable lesion by investigator assessment based on RECIST v1.1.

- * ECOG performance status of 0 or 1
Cohort E
* Histopathologically-confirmed LA/mUC, including UC originating from the renal pelvis, ureters, bladder, or urethra

- * No prior systemic therapy for LA/mUC
* Neoadjuvant or adjuvant therapy, including PD-(L)1 inhibitors, is acceptable, if disease recurrence/progression occurred more than 12 months after the last dose of systemic therapy.

- * At least one measurable lesion by investigator assessment based on RECIST v1.1.

- * Participant is eligible to receive cisplatin- or carboplatin- containing chemotherapy per investigator evaluation

- * HER2-expression status determined by the central laboratory to be IHC 1+, 2+ or 3+, in the provided tumor sample

- * ECOG performance status of 0 or 1
Cohort G
* Histopathologically-confirmed, locally-advanced, unresectable or metastatic urothelial cancer (LA/mUC), including UC originating from the renal pelvis, ureters, bladder, or urethra

- * Participants must have received only 1 or 2 lines of prior systemic treatment for LA/mUC, including 1 line of therapy containing enfortumab vedotin as monotherapy or in combination with pembrolizumab
* The last administration of enfortumab vedotin must be 90 days from the start of study treatment. Intervening therapies are allowed between the final dose of enfortumab vedotin and the start of disitamab vedotin.

- * At least one measurable lesion by investigator assessment based on RECIST version 1.1.

- * HER2-expression status determined by the central laboratory to be IHC 1+, 2+ or 3+, in the provided tumor sample

- * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
Exclusion Criteria:
Cohorts A and B
* Known hypersensitivity to disitamab vedotin or any of their components

- * Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study (defined as Cycle 1 Day 1 for Cohorts A and B)

- * Toxicity from a previous treatment has not returned to Grades 0 or 1 (except for Grade 2 alopecia)

- * Prior MMAE-based ADCs (eg, enfortumab vedotin) or HER2-directed therapy

- * Major surgery that has not fully recovered within 4 weeks prior to dose administration

- * Peripheral sensory or motor neuropathy ≥ Grade 2 at baseline
Cohort C
* Known hypersensitivity to disitamab vedotin, pembrolizumab, or any of their components

- * Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study defined as Cycle 1 Day 1 for the single-arm part of Cohort C and as randomization date for the randomized part of Cohort C)

- * Toxicity from a previous treatment has not returned to Grades 0 or 1 (except for Grade 2 alopecia)

- * Prior MMAE-based ADCs (eg, enfortumab vedotin) or HER2-directed therapy

- * Major surgery that has not fully recovered within 4 weeks prior to dose administration

- * Peripheral sensory or motor neuropathy ≥ Grade 2 at baseline

- * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug

- * Participants who have previously received any prior treatment with an agent directed to another stimulatory or co-inhibitory T cell receptor (including but not limited to CD137 agonists, CAR-T cell therapy, CTLA-4 inhibitors, or OX-40 agonists) are excluded.
Cohort D
* Known hypersensitivity to disitamab vedotin or any of their components

- * Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study (defined as Cycle 1 Day 1 for Cohort D)

- * Toxicity from a previous treatment has not returned to Grades 0 or 1 (except for Grade 2 alopecia)

- * Prior HER2-directed therapy

- * Any prior history of ≥ Grade 3 non-hematological AEs related to prior therapy

- * Major surgery that has not fully recovered within 4 weeks prior to dose administration

- * Peripheral sensory or motor neuropathy ≥ Grade 1 at baseline
Cohort E
* Known hypersensitivity to disitamab vedotin, pembrolizumab, or any of their components

- * Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study (defined as Cycle 1 Day 1 for Cohort E)

- * Toxicity from a previous treatment has not returned to Grades 0 or 1 (except for Grade 2 alopecia)

- * Any prior history of ≥ Grade 3 non-hematological AEs related to prior therapy

- * Prior MMAE-based ADCs (eg, enfortumab vedotin) or HER2-directed therapy

- * Major surgery that has not fully recovered within 4 weeks prior to dose administration

- * Peripheral sensory or motor neuropathy ≥ Grade 1 at baseline

- * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug
Cohort G
* Known hypersensitivity to disitamab vedotin or any of their components

- * Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study (defined as Cycle 1 Day 1 for Cohort G)

- * Toxicity from a previous treatment has not returned to Grades 0 or 1 (except for Grade 2 alopecia)

- * Prior HER2-directed therapy

- * Major surgery that has not fully recovered within 4 weeks prior to dose administration

- * Peripheral sensory or motor neuropathy ≥ Grade 2 at baseline
There are additional inclusion and exclusion criteria. The study center will determine if criteria for participation are met.

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Pfizer CT.gov Call Center

Role: Study Director

Affiliation: Pfizer

Overall Contact

Name: Pfizer CT.gov Call Center

Phone: 1-800-718-1021

Email: [email protected]

LOCATION

Facility Status Contact
Facility: Banner Gateway Medical Center
Gilbert, Arizona 85234
United States
Status: Recruiting Contact: N/A
Facility: Banner MD Anderson Cancer Center
Gilbert, Arizona 85234
United States
Status: Recruiting Contact: N/A
Facility: Kaiser Permanente Anaheim Kraemer Medical Offices
Anaheim, California 92806
United States
Status: Recruiting Contact: N/A
Facility: Kaiser Permanente Baldwin Park Medical Center
Baldwin Park, California 91706
United States
Status: Recruiting Contact: N/A
Facility: Kaiser Permanente Bellflower Medical Offices
Bellflower, California 90706
United States
Status: Recruiting Contact: N/A
Facility: Kaiser Permanente Fontana Medical Center
Fontana, California 92335
United States
Status: Recruiting Contact: N/A
Facility: Kaiser Permanente South Bay Medical center
Harbor City, California 90710
United States
Status: Recruiting Contact: N/A
Facility: Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California 92612
United States
Status: Recruiting Contact: N/A
Facility: UCI Health - Irvine Infusion Pharmacy ACC
Irvine, California 92612
United States
Status: Recruiting Contact: N/A
Facility: Kaiser Permanente Alton/Sand Canyon Medical Offices
Irvine, California 92618
United States
Status: Recruiting Contact: N/A
Facility: Kaiser Permanente Los Angeles Medical Offices
Los Angeles, California 90027
United States
Status: Recruiting Contact: N/A
Facility: Kaiser Permanente West Los Angeles Medical Center
Los Angeles, California 90034
United States
Status: Recruiting Contact: N/A
Facility: Ronald Reagan UCLA Medical Center, Drug Information Center
Los Angeles, California 90095
United States
Status: Recruiting Contact: N/A
Facility: UCLA Hematology Oncology
Los Angeles, California 90095
United States
Status: Recruiting Contact: N/A
Facility: Kaiser Permanente Ontario Medical Center
Ontario, California 91761
United States
Status: Recruiting Contact: N/A
Facility: UC Irvine Health
Orange, California 92868
United States
Status: Recruiting Contact: N/A
Facility: UC Irvine Medical Center
Orange, California 92868
United States
Status: Recruiting Contact: N/A
Facility: Kaiser Permanente Panorama City Medical Center, Medical Offices 3
Panorama City, California 91402
United States
Status: Recruiting Contact: N/A
Facility: Kaiser Permanente Riverside Medical Center
Riverside, California 92505
United States
Status: Recruiting Contact: N/A
Facility: Kaiser Permanente San Diego Mission Road (Regulatory and Lab Supplies)
San Diego, California 92108
United States
Status: Recruiting Contact: N/A
Facility: Kaiser Permanente Zion Medical Center
San Diego, California 92120
United States
Status: Recruiting Contact: N/A
Facility: UCSF Cancer Center MZ Phlebotomy
San Francisco, California 94115
United States
Status: Recruiting Contact: N/A
Facility: UCSF Mount Zion Phlebotomy
San Francisco, California 94115
United States
Status: Recruiting Contact: N/A
Facility: UCSF Parnassus Phlebotomy
San Francisco, California 94143
United States
Status: Recruiting Contact: N/A
Facility: UCSF Investigational Drugs Pharmacy
San Francisco, California 94158
United States
Status: Recruiting Contact: N/A
Facility: University of California, San Francisco | HDFCCC - Hematopoietic Malignancies
San Francisco, California 94158
United States
Status: Recruiting Contact: N/A
Facility: University of California, San Francisco
San Francisco, California 94158
United States
Status: Recruiting Contact: N/A
Facility: Kaiser Permanente San Marcos Medical Offices
San Marcos, California 92078
United States
Status: Recruiting Contact: N/A
Facility: UCLA Hematology/Oncology - Santa Monica
Santa Monica, California 90404
United States
Status: Recruiting Contact: N/A
Facility: Kaiser Permanente Woodland Hills Medical Center
Woodland Hills, California 91367
United States
Status: Recruiting Contact: N/A
Facility: Florida Cancer Specialists
Bonita Springs, Florida 34135
United States
Status: Recruiting Contact: N/A
Facility: Florida Cancer Specialists
Bradenton, Florida 34205
United States
Status: Recruiting Contact: N/A
Facility: Florida Cancer Specialists
Bradenton, Florida 34211
United States
Status: Recruiting Contact: N/A
Facility: Florida Cancer Specialists
Cape Coral, Florida 33909
United States
Status: Recruiting Contact: N/A
Facility: Florida Cancer Specialists
Fleming Island, Florida 32003
United States
Status: Recruiting Contact: N/A
Facility: Florida Cancer Specialists
Fort Myers, Florida 33905
United States
Status: Recruiting Contact: N/A
Facility: Florida Cancer Specialists
Fort Myers, Florida 33908
United States
Status: Recruiting Contact: N/A
Facility: Florida Cancer Specialists
Naples, Florida 34102
United States
Status: Recruiting Contact: N/A
Facility: Florida Cancer Specialists
Port Charlotte, Florida 33980
United States
Status: Recruiting Contact: N/A
Facility: Florida Cancer Specialists
Sarasota, Florida 34232
United States
Status: Recruiting Contact: N/A
Facility: Florida Cancer Specialists
Sarasota, Florida 34236
United States
Status: Recruiting Contact: N/A
Facility: Florida Cancer Specialists
Tallahassee, Florida 32308
United States
Status: Recruiting Contact: N/A
Facility: Moffitt Cancer Center McKinley Hospital
Tampa, Florida 33612
United States
Status: Recruiting Contact: N/A
Facility: Florida Cancer Specialists
Venice, Florida 34285
United States
Status: Recruiting Contact: N/A
Facility: Florida Cancer Specialists
Venice, Florida 34292
United States
Status: Recruiting Contact: N/A
Facility: Northwest Georgia Oncology Centers, a Service of Tanner Medical Center Villa Rica
Carrollton, Georgia 30117
United States
Status: Recruiting Contact: N/A
Facility: West Georgia Infusion Center, a Service of Tanner Medical Center Villa Rica
Carrollton, Georgia 30117
United States
Status: Recruiting Contact: N/A
Facility: Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital
Cartersville, Georgia 30121
United States
Status: Recruiting Contact: N/A
Facility: Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital
Douglasville, Georgia 30134
United States
Status: Recruiting Contact: N/A
Facility: Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital
Hiram, Georgia 30141
United States
Status: Recruiting Contact: N/A
Facility: WellStar Paulding Hospital
Hiram, Georgia 30141
United States
Status: Recruiting Contact: N/A
Facility: Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital
Marietta, Georgia 30060
United States
Status: Recruiting Contact: N/A
Facility: Northwest Georgia Oncology Centers
Marietta, Georgia 30060
United States
Status: Recruiting Contact: N/A
Facility: UChicago Medicine - River East
Chicago, Illinois 60611
United States
Status: Recruiting Contact: N/A
Facility: The University of Chicago Medical Center, CCD - Investigational Drug Service Pharmacy
Chicago, Illinois 60637
United States
Status: Recruiting Contact: N/A
Facility: University of Chicago Medical Center
Chicago, Illinois 60637
United States
Status: Recruiting Contact: N/A
Facility: Accellacare - Deerfield
Deerfield, Illinois 60015
United States
Status: Recruiting Contact: N/A
Facility: UChicago Medicine at Ingalls - Flossmoor
Flossmoor, Illinois 60422
United States
Status: Recruiting Contact: N/A
Facility: UChicago Medicine Ingalls Memorial
Harvey, Illinois 60426
United States
Status: Recruiting Contact: N/A
Facility: University of Chicago Comprehensive Cancer Center at Silver Cross Hospital
New Lenox, Illinois 60451
United States
Status: Recruiting Contact: N/A
Facility: The University of Chicago Medicine Center for Advanced Care Orland Park
Orland Park, Illinois 60462
United States
Status: Recruiting Contact: N/A
Facility: UChicago Medicine at Ingalls - Tinley Park
Tinley Park, Illinois 60477
United States
Status: Recruiting Contact: N/A
Facility: UMass Memorial Medical Center
Worcester, Massachusetts 01655
United States
Status: Recruiting Contact: N/A
Facility: University of Massachusetts Chan Medical School
Worcester, Massachusetts 01655
United States
Status: Recruiting Contact: N/A
Facility: Karmanos Cancer Institute
Detroit, Michigan 48201
United States
Status: Recruiting Contact: N/A
Facility: Henry Ford Hospital
Detroit, Michigan 48202
United States
Status: Recruiting Contact: N/A
Facility: Karmanos Cancer Institute Weisberg Cancer Treatment Center
Farmington Hills, Michigan 48334
United States
Status: Recruiting Contact: N/A
Facility: Cancer & Hematology Centers of Western Michigan, PC
Grand Rapids, Michigan 49503
United States
Status: Recruiting Contact: N/A
Facility: Cancer & Hematology Centers of Western Michigan, PC- Kit Storage
Grand Rapids, Michigan 49546
United States
Status: Recruiting Contact: N/A
Facility: Cancer & Hematology Centers of Western Michigan, PC
Holland, Michigan 49424
United States
Status: Recruiting Contact: N/A
Facility: Karmanos Cancer Institute at McLaren Greater Lansing
Lansing, Michigan 48910
United States
Status: Recruiting Contact: N/A
Facility: Cancer & Hematology Centers of Western Michigan, PC
Norton Shores, Michigan 49444
United States
Status: Recruiting Contact: N/A
Facility: MSK Basking Ridge
Basking Ridge, New Jersey 07920
United States
Status: Recruiting Contact: N/A
Facility: MSK Monmouth
Middletown, New Jersey 07748
United States
Status: Recruiting Contact: N/A
Facility: MSK Bergen
Montvale, New Jersey 07645
United States
Status: Recruiting Contact: N/A
Facility: MSK Wesrchester
Harrison, New York 10604
United States
Status: Recruiting Contact: N/A
Facility: Northwell Health
Lake Success, New York 11042
United States
Status: Recruiting Contact: N/A
Facility: Memorial Sloan Kattering Cancer Centre- Investigational Drug Service Pharmacy
Long Island City, New York 11101
United States
Status: Recruiting Contact: N/A
Facility: Ship study drug to: Mount Sinai Hospital- Pharmacy Dept
New York, New York 10029
United States
Status: Recruiting Contact: N/A
Facility: Evelyn H. Lauder Breast and Imaging Centre (BAIC)
New York, New York 10065
United States
Status: Recruiting Contact: N/A
Facility: Memorial Sloan Kettering Cancer Center - Main Campus
New York, New York 10065
United States
Status: Recruiting Contact: N/A
Facility: Sidney Kimmel Centre for Prostate and Urological Cancer
New York, New York 10065
United States
Status: Recruiting Contact: N/A
Facility: MSK nassau
Uniondale, New York 11553
United States
Status: Recruiting Contact: N/A
Facility: Carolinas Medical Center (biopsy only)
Charlotte, North Carolina 28203
United States
Status: Recruiting Contact: N/A
Facility: Carolinas Medical Center Investigational Drug Services
Charlotte, North Carolina 28204
United States
Status: Recruiting Contact: N/A
Facility: Levine Cancer Institute
Charlotte, North Carolina 28204
United States
Status: Recruiting Contact: N/A
Facility: Atrium Health Mercy (biopsy only)
Charlotte, North Carolina 28207
United States
Status: Recruiting Contact: N/A
Facility: Atrium Health Pineville (biopsy only)
Charlotte, North Carolina 28210
United States
Status: Recruiting Contact: N/A
Facility: Atrium Health University City (biopsy only)
Charlotte, North Carolina 28262
United States
Status: Recruiting Contact: N/A
Facility: Levine Cancer Institute University
Charlotte, North Carolina 28262
United States
Status: Recruiting Contact: N/A
Facility: Levine Cancer Institute - Ballantyne
Charlotte, North Carolina 28277
United States
Status: Recruiting Contact: N/A
Facility: Atrium Health Cabarrus (biopsy only)
Concord, North Carolina 28025
United States
Status: Recruiting Contact: N/A
Facility: Levine Cancer Institute Concord
Concord, North Carolina 28025
United States
Status: Recruiting Contact: N/A
Facility: Atrium Health Union (biopsy only)
Monroe, North Carolina 28112
United States
Status: Recruiting Contact: N/A
Facility: University Hospitals Cleveland Medical Center
Cleveland, Ohio 44106
United States
Status: Recruiting Contact: N/A
Facility: OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma 73104
United States
Status: Recruiting Contact: N/A
Facility: University of Tennessee Medical Center
Knoxville, Tennessee 37920
United States
Status: Recruiting Contact: N/A
Facility: The University of Texas MD Anderson Cancer Center
Houston, Texas 77030
United States
Status: Recruiting Contact: N/A
Facility: Inova Schar Cancer Institute Infusion Pharmacy
Fairfax, Virginia 22031
United States
Status: Recruiting Contact: N/A
Facility: Inova Schar Cancer Institute
Fairfax, Virginia 22031
United States
Status: Recruiting Contact: N/A
Facility: Harborview Medical Center
Seattle, Washington 98104
United States
Status: Recruiting Contact: N/A
Facility: Fred Hutchinson Cancer Center
Seattle, Washington 98109
United States
Status: Recruiting Contact: N/A
Facility: University of Washington Medical Center
Seattle, Washington 98195
United States
Status: Recruiting Contact: N/A
Facility: Froedtert Hospital/Medical College of Wisconsin
Milwaukee, Wisconsin 53226
United States
Status: Recruiting Contact: N/A